NASDAQ

Updated Nov 3, 7:59 PM ET

SYRE

Spyre Therapeutics, Inc.
$93.00CS band Mixed

+$3.76 (3.94%) At close $99.27 · Today

☾After Hours −$6.27 (6.32%) Nov 3, 7:59 PM ET

Mkt Cap
$8.8B
Volume
906K
52W High
$110.18
52W Low
$21.15
PE Ratio
—
Avg Vol
1.3M
As of 11/2/26
Div Yield
—
Beta
1.75
As of 11/2/26

Company

Headquarters
Waltham, MA
Employees
112 (2026)
Listed
Apr 7, 2016
Exchange
Nasdaq
Website
spyre.com
SEC industry
Pharmaceutical Preparations
Cylvex sector
Health Care · Pharmaceuticals

Pharmaceuticals

  • Market cap #33 of 430
  • P/B #58 of 396

Ranked highest first among stocks Cylvex covers.

  1. LLYEli Lilly and Company$1.26T-0.11%
  2. JNJJohnson & Johnson$640.8B-1.62%
  3. ABBVAbbVie Inc$505.4B-0.98%
  4. MRKMerck & Co Inc$356.9B-2.49%
  5. NVSNovartis AG$300.8B-1.40%
All Pharmaceuticals ›

Financial summary

Related companies

About

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

From company filings and market data · Not investment advice

Price data

Day Low $95.52Day High $100.09
52W Low $21.1552W High $110.18
Open
$97.04
Prev Close
$95.51
Volume
906.0K
Avg Vol (30D)
1.3M

52W range and average volume from daily bars (unadjusted, last 252 sessions).

Financials

Consensus estimates

The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.